The future of Belgium’s pharmaceutical industry is under scrutiny as competition challenges Belgian success. Leading Belgian politicians discussed revamping pharma’s road map in a recent conversation with Euractiv.
“The federally voted roadmap turns out to be ‘an empty box’, with necessary execution decrees still pending. This creates uncertainty for an industry making far-reaching commitments without clear compensations,”…
